Retatrutide vs Tirzepatide

Retatrutide's Phase 2 trial (Jastreboff et al., NEJM 2023) enrolled 338 adults with obesity (BMI ≥30, or ≥27 with weight-related comorbidity but not type 2 diabetes). After 48 weeks at the 12 mg dose, the mean weight reduction was approximately 24.2% — the largest effect reported for any pharmacological agent in the GLP-1-related class. The placebo arm lost approximately 2.1%. The trial was not designed for direct comparison against tirzepatide and used different inclusion criteria.

Tirzepatide's SURMOUNT-1 trial (Phase 3, 2,539 adults with obesity) reported approximately 22.5% mean weight reduction at 72 weeks at the 15 mg dose. The placebo arm lost approximately 2.4%. Tirzepatide is also FDA-approved for type 2 diabetes via the SURPASS trial program (Mounjaro brand), where it produced HbA1c reductions of 1.8–2.4 percentage points alongside 8–13 kg weight loss.

Important caveats when comparing the two figures: retatrutide's 24% is from a 48-week Phase 2 trial; tirzepatide's 22.5% is from a 72-week Phase 3 trial. Direct head-to-head data does not yet exist. Phase 3 retatrutide results (the TRIUMPH program) are expected in 2026–2027 and may revise the magnitude of effect — Phase 3 trials often produce slightly smaller effects than Phase 2 due to broader patient populations and longer follow-up.

Both peptides share the GLP-1-class adverse-event profile, dominated by gastrointestinal symptoms during dose titration. Symptoms typically peak in the first 4–8 weeks of each dose increase and attenuate over time. Common events reported in trials of both compounds include nausea, vomiting, diarrhoea, constipation, decreased appetite (intended effect, but counted as an adverse event), and injection-site reactions.

Less common or serious events seen in either trial program include gallbladder events (cholelithiasis, cholecystitis) — an elevated rate is consistent across the GLP-1 class — pancreatitis (rare, class-warning), increased heart rate, and the medullary thyroid carcinoma boxed warning carried by tirzepatide based on rodent data (applicability to humans unknown). Retatrutide's published safety database is much smaller, so rare-event characterisation is incomplete.

Retatrutide-specific safety questions centre on glucagon receptor activation. Phase 2 data did not show clinically significant hyperglycaemia in non-diabetic participants, but the long-term effect in diabetic populations remains an open question — one of the primary reasons Phase 3 trials are required before any approval.

This decision belongs with a licensed prescriber who knows the patient's medical history. The summary below describes the published trade-offs, not a recommendation.

Tirzepatide is the option with the longer real-world track record, FDA approval (and the regulatory oversight that entails), known insurance pathways, and a cleaner glycemic profile. It has the largest body of long-term safety data of any compound in the GLP-1-related class for obesity.

Retatrutide is the option with the largest reported weight-reduction effect to date, but the smallest published safety database. Its triple-agonist mechanism is a meaningfully different drug-design approach. Patients enrolled in clinical trials or sourcing through regulated compounding accept the trade-off: greater weight-reduction potential in exchange for less long-term safety data. Patients with type 2 diabetes have specific reasons to prefer tirzepatide today; patients without diabetes who prioritise maximum weight reduction may discuss retatrutide with their prescriber.